Antigenics, Inc. (NASDAQ:AGEN)

7dogs (96.87) Submitted: 4/8/2008 2:08:49 PM : Start Price: $17.44 AGEN Score: -70.69

News today about Antigenics. Approval in Russia for Oncophage for use in treatment of kidney cancer patients. This is a personalized vaccine made from the individual patient's tumor to prevent recurrence of the cancer. Very interesting.

mjc727 (< 20) Submitted: 3/3/2008 11:17:15 AM : Start Price: $13.86 AGEN Score: -66.16

Cancer vaccines

jogger21 (< 20) Submitted: 11/21/2007 10:20:24 AM : Start Price: $12.72 AGEN Score: -56.05

They have applied for approval to market their drug in Russia. They are are also planning to seek approval to market in Europe, Canada, and Asia.

jbell9201 (< 20) Submitted: 9/27/2007 10:53:02 PM : Start Price: $14.40 AGEN Score: -54.44

Antigenics cancer vaccine stands a modest chance of Russian and European approval, and even without approval, another Antigenics product, QS21, an adjunct to vaccines, improving the immune response, shows great promise, currently undergoing a promising

trial in Glaxo Smith Kline's Malaria vaccine.

Antigenics Oncophage vaccine, using a novel

approach of incubating individual tumor tissue with a propietary heat-protein, then reinjecting the resulting vaccine into the

individual from whom the tumor tissue was removed shows some promise in heretofore refractory malignancies such as Glioblastoma,

a highly aggressive brain tumor, and early metastatic Renal cancer. Even limited success

should prove rewarding to patient investors.

BRM13 (< 20) Submitted: 5/30/2007 2:12:21 PM : Start Price: $16.32 AGEN Score: -59.80

I OWN SOME

Ernbo6 (57.95) Submitted: 5/15/2007 1:43:13 PM : Start Price: $18.48 AGEN Score: +64.40

Antigenics Inc. is a biotechnology company developing technologies and products to treat cancers, infectious diseases and autoimmune disorders, primarily based on immunological approaches. Its advanced product candidate is Oncophage (vitespen, formerly HSPPC-96), a personalized therapeutic cancer vaccine candidate being tested for several cancer indications. The Company's product candidate portfolio includes Oncophage (vitespen; formerly HSPPC-96), a personalized therapeutic cancer vaccine candidate that has been tested, or is being tested, in several cancer indications, including in Phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma. Oncophage is also being tested in Phase II and Phase I clinical trials in a range of indications
Put this on a watchlist...keep looking for the updates since this can be another Dendreon.

xdogg (< 20) Submitted: 4/30/2007 2:33:12 PM : Start Price: $19.50 AGEN Score: +66.85

Following the crowd...

TracksManning (< 20) Submitted: 4/27/2007 7:55:26 PM : Start Price: $19.44 AGEN Score: -66.58

It's been diving down straight for the past 5 days. It's about time to reverse up for this Biotech stock. Good time to get in.

jeff6045 (< 20) Submitted: 4/24/2007 8:57:03 PM : Start Price: $21.90 AGEN Score: -70.16

Successful brain cancer drug. Sales should carry it forward.

amteague777 (96.52) Submitted: 4/19/2007 2:59:13 PM : Start Price: $21.54 AGEN Score: +70.83

Consistent loss of shareholder equity, cash and assets since 2002.

TopDup (49.17) Submitted: 4/16/2007 6:36:17 PM : Start Price: $25.29 AGEN Score: -74.46

Oncophage results announced today look promising. This stock will either crash (again), or shoot up based on continued results. Don't put any money in this one you can't afford to lose.